Last reviewed · How we verify

Diclofenac diethylamine

Taisho Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Acute pain and inflammation, Musculoskeletal pain and inflammation, Postoperative pain.

At a glance

Generic nameDiclofenac diethylamine
SponsorTaisho Pharmaceutical Co., Ltd.
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Rheumatology, Inflammation
PhasePhase 3

Mechanism of action

Diclofenac diethylamine is a salt formulation of diclofenac designed for topical or systemic delivery. It works by inhibiting both COX-1 and COX-2 enzymes, which catalyze prostaglandin production. By reducing prostaglandins, the drug decreases inflammatory mediators and provides analgesic and anti-inflammatory effects. The diethylamine salt form may enhance absorption and bioavailability compared to the base diclofenac.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: